A study in Scientific Reports found that patients with type 2 diabetes who were treated with metformin for a longer period of time, as well as with higher doses of the drug, had lower levels of cobalamin and more severe diabetic peripheral neuropathy, compared with patients who were not treated with metformin. The findings indicate that clinicians should monitor levels of cobalamin, serum methylmalonic acid and homocysteine in diabetes patients who are also longtime metformin users to mitigate risk of DPN symptoms.
Longtime metformin use tied to more severe DPN in T2D
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.